A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE).

Trial Summary

Age Range
18 - 65 years
Conditions the trial is for
Lupus (SLE)
What the trial is testing?
LY3361237
Could I receive a Placebo?
Yes
Enrollment Goal
85
Trial Dates
Mar 7, 2022 - Dec 29, 2023
How long will I be in the trial?
Your participation could last about 34 weeks and may include up to 15 visits to the study center.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have systemic lupus erythematosus at least for the last 24 weeks

  • Participants must be receiving NSAID, antimalarial, steroids or medications that reduce strength of body's immune response

Participants Must Not:

  • Participants must not have been taking oral steroids at more than 20 milligrams daily

  • Participants must not have an active infection at least for the last 30 days

  • Participants must not have hepatitis B or hepatitis C, human immunodeficiency virus (HIV) infection or tuberculosis (TB)

  • Participants must not have active fibromyalgia

  • Participants must not have had a unstable heart disease within the last 24 weeks

  • Participants must not have serious medical condition that could interfere with the analysis of the study

  • Participants must not have serious risk for suicide

  • Participants must not be pregnant or nursing

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources